Skip to main navigation
Skip to search
Skip to main content
WashU Medicine Research Profiles Home
Help & FAQ
Link opens in a new tab
Search content at WashU Medicine Research Profiles
Home
Profiles
Departments, Divisions and Centers
Research output
Therapeutic decision making in BMT/SCT for hemoglobinopathies
Shalini Shenoy
, Reinhold Munker
, Kerry Atkinson
Institute of Clinical and Translational Sciences (ICTS)
Siteman Cancer Center
Division of Hematology & Oncology
Research output
:
Chapter in Book/Report/Conference proceeding
›
Chapter
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Therapeutic decision making in BMT/SCT for hemoglobinopathies'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Sickle Cell Disease
100%
Therapeutic Decision-making
100%
Hemoglobinopathies
100%
Allogeneic Transplant
62%
Thalassemia
50%
Conventional Therapy
50%
β-Thalassemia (β-thal)
50%
HLA-matched Donor
25%
Poor Quality of Life
12%
Pretransplant
12%
Overall Survival
12%
Myeloablative
12%
Infection Rate
12%
Disease-free Survival
12%
Transfusion
12%
Therapeutic Potential
12%
Child Age
12%
Disease-specific
12%
Organ Damage
12%
Cyclophosphamide
12%
Severe Cases
12%
Organ Dysfunction
12%
Reduced-intensity Conditioning
12%
CIBMTR
12%
Busulfan
12%
Vital Organs
12%
Chelation Therapy
12%
Cord Blood Transplantation
12%
Medicine and Dentistry
Decision Making
100%
Sickle-Cell Disease
100%
Hemoglobinopathy
100%
Thalassemia
50%
Thalassemia Major
50%
Overall Survival
12%
Quality of Life
12%
Conditioning
12%
Disease Free Survival
12%
Contraindication
12%
Cyclophosphamide
12%
Cord Blood
12%
Reduced Intensity Conditioning
12%
Busulfan
12%
Chelation Therapy
12%
Diseases
12%
Organ Dysfunction
12%